Essendrop R, Friedline N, Cruz J. 19(3). 14 - 16. (Case Reports)
Abstract
Presumptive antirelapse therapy (PART) with primaquine for Plasmodium vivax malaria postdeployment is an important component of the US military Force Health Protection plan. While primaquine is well tolerated in the majority of cases, we present a unique case of an active duty Army Ranger without glucose-6-phosphatase dehydrogenase or cytochrome b5 reductase (b5R) deficiencies who developed symptomatic methemoglobinemia while taking PART following a deployment to Afghanistan.
Keywords: presumptive antirelapse therapy; Plasmodium vivax; primaquine; methemoglobinemia